Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099980 · ClinicalTrials.gov registry record · Early Phase 1
Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa
A Early Phase 1 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03099980 is a Early Phase 1 study that has completed, run by Tufts Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT03099980, a Early Phase 1 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a pilot study in which the the safety and feasibility of secukinumab in HS patients as well as information about the effect size will be determined in order to inform a future larger randomized control trial with an active comparator.
Interventions
- BIOLOGICAL secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-07-11 |
| Est. Completion | 2019-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099980
The ClinicalTrials.gov registry entry for NCT03099980 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which secukinumab is the first listed.
NCT03099980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03099980 about?
NCT03099980 is a clinical study titled "Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa". This is a pilot study in which the the safety and feasibility of secukinumab in HS patients as well as information about the effect size will be determined in order to inform a future larger randomized control trial with an active comparator.
What is the current status of trial NCT03099980?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2016-07-11. Estimated completion is 2019-01.
What interventions are being tested in trial NCT03099980?
The interventions under investigation include: secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03099980?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.